Yearly Archives: 2022

PSNC’s Pricing Audit Team have noted seeing an increase in unsigned patient declarations for patients who are age exempt where the date of birth is handwritten. Pharmacy teams are reminded that where the date of birth is handwritten the patient declaration on the reverse of the prescription MUST be completed in full, i.e. exemption box [...]

The post Reminder: Completing patient declarations for age exempt patients appeared first on PSNC Website.

Community pharmacy contractors can now access the assessment framework on PharmOutcomes for the 2022/23 Pharmacy Quality Scheme (PQS). This is available free of charge to all contractors. The assessment framework allows contractors and their teams to track their progress with achieving the gateway and quality criteria/domains of the PQS. Once a contractor has logged into PharmOutcomes, [...]

The post PQS: Assessment framework now available appeared first on PSNC Website.

The Department of Health and Social Care (DHSC) has today (22/11/2022) granted the following list of price concessions for November 2022: Drug Pack size Price concession Alendronic acid 70mg tablets 4 £5.36 Amisulpride 100mg tablets 60 £20.29 Amisulpride 200mg tablets 60 £33.92 Amisulpride 50mg tablets 60 £13.09 Amorolfine 5% medicated nail lacquer 5 £7.34 Aripiprazole [...]

The post November 2022 Price Concessions 2nd Update appeared first on PSNC Website.

NHS Digital is asking community pharmacy team members to share their experience of using the Electronic Prescription Service (EPS) by volunteering to take part with a short EPS interview. Such user feedback is essential to informing the future development of the system ahead of the planned launch of the next generation of EPS. PSNC and [...]

The post Help improve the Electronic Prescription Service appeared first on PSNC Website.

Class 4 Medicines Defect Information: Hyoscine Butylbromide 20 mg film-coated tablets (Morningside Healthcare Limited) Drug alert number: EL (22)A/48 Date issued: 21 November 2022 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Hyoscine Butylbromide 20 mg film-coated tablets, PL 20117/0349 Batch Number Expiry Date Pack [...]

The post MHRA – Class 4 Medicines Defect Information: Hyoscine Butylbromide 20 mg film-coated tablets (Morningside Healthcare Limited) appeared first on PSNC Website.